Core Viewpoint - The document outlines the information disclosure management measures for Sanofi Health Industry (Shanghai) Co., Ltd., emphasizing the importance of timely, accurate, and complete information disclosure to protect the rights of shareholders and the public [1]. Group 1: General Principles of Information Disclosure - The company must disclose all information that could significantly impact the trading price of its stocks or investment decisions [6][7]. - Information must be disclosed in a timely, fair, and accurate manner, ensuring clarity and avoiding misleading statements [7][8]. - All investors should have equal access to disclosed information, preventing selective disclosure [11]. Group 2: Responsibilities and Obligations - The chairman of the board is the primary responsible person for information disclosure, while the board secretary is responsible for its execution [2]. - All related parties, including directors, senior management, and shareholders, have disclosure obligations [2][3]. - The company must ensure that any public commitments made by related parties are disclosed promptly [3]. Group 3: Disclosure of Major Events - Major events must be disclosed immediately upon the board's resolution or when relevant parties sign agreements [12]. - If a major event is uncertain, the company may delay disclosure but must do so at the latest when a final decision is made [12]. - The company must disclose any significant changes to previously disclosed matters that could impact stock prices [14]. Group 4: Content of Disclosure - The company must disclose information reflecting its business, technology, finance, governance, competitive advantages, industry trends, and policy impacts [6]. - Regular disclosures should include annual, semi-annual, and quarterly reports, detailing financial data and significant events [30][31]. - The company must provide detailed explanations for any significant declines in net profit or revenue [26]. Group 5: Industry Information and Risks - The company should proactively disclose industry information that could significantly affect stock prices or investor decisions [59]. - It must identify and disclose risks that could adversely impact its core competitiveness and operational activities [64][65]. - Any major changes in the industry environment or operational risks must be disclosed promptly [67].

Core Points - The article outlines the independent director system of Sanofi (Shanghai) Pharmaceutical Co., Ltd, emphasizing the importance of independent directors in enhancing corporate governance and protecting minority shareholders' rights [1][2][3] Group 1: Independent Director Definition and Responsibilities - Independent directors must not hold any other positions within the company and should have no direct or indirect interests that could affect their independent judgment [1][2] - They are responsible for participating in decision-making, supervising potential conflicts of interest, and providing professional advice to enhance the board's decision-making quality [20][21] Group 2: Qualifications and Conditions for Independent Directors - Candidates for independent directors must meet specific legal and regulatory requirements, including independence from the company and its major shareholders [7][8] - Independent directors should have relevant experience, such as at least five years in legal, accounting, or economic fields, and must not have any significant negative records [10][11] Group 3: Nomination and Election Process - Independent directors can be nominated by the board or shareholders holding more than 1% of the company's shares, and the nomination must be free from conflicts of interest [13][14] - The election of independent directors requires a cumulative voting system when electing multiple directors, ensuring transparency and representation of minority shareholders [16][17] Group 4: Duties and Powers of Independent Directors - Independent directors have the authority to independently hire external consultants for audits or advice, propose meetings, and express independent opinions on matters that may harm the company or minority shareholders [21][22] - They are required to attend board meetings and can delegate their voting rights to other independent directors if unable to attend [27][28] Group 5: Reporting and Communication - Independent directors must submit annual reports detailing their attendance, participation in committees, and communication with minority shareholders [35][36] - They are also responsible for reporting any violations of laws or regulations to the board and can escalate issues to regulatory authorities if necessary [10][17] Group 6: Compensation and Support - The company is responsible for covering the costs incurred by independent directors in fulfilling their duties, including hiring professional services [40] - Independent directors receive appropriate compensation, which must be approved by the board and disclosed in the annual report [41][42]

General Principles - The rules aim to clarify the responsibilities and authority of the board of directors of Sangfor Technologies (Shanghai) Co., Ltd., ensuring efficient operation and scientific decision-making [1] - The board is a permanent institution responsible for executing shareholder resolutions and safeguarding the interests of the company and all shareholders [1][2] - The board must act within the scope defined by laws, regulations, and the company's articles of association, treating all shareholders fairly [1][3] Board Structure - The board has a secretariat responsible for daily affairs, including document management and information disclosure [2][3] - The board is supported by specialized committees, including the Audit Committee, Compensation and Assessment Committee, Nomination Committee, and Strategic Decision Committee [2][3] Meeting Procedures - The board holds two regular meetings annually to review annual and semi-annual performance [4] - Special meetings can be convened under specific circumstances, such as requests from the chairman or other board members [4][5] - Meeting proposals must comply with legal and regulatory requirements and be submitted in a timely manner [5][6] Notification and Attendance - Regular meetings require a 10-day notice, while special meetings require a 5-day notice, unless urgent circumstances arise [7][8] - Attendance is mandatory for directors, and they may delegate their voting rights under specific conditions [9][10] Decision-Making and Voting - Decisions require a majority vote from attending directors, with specific rules for related party transactions [11][12] - Meeting minutes must be recorded, detailing attendance, discussions, and voting outcomes [14][15] Documentation and Record Keeping - Meeting records and resolutions are maintained by the board secretary for a period of ten years [15][16] - The board may establish a special fund with shareholder approval, managed by the board secretary [56][57]

General Provisions - The company is established as a joint-stock limited company in accordance with the Company Law and other relevant regulations [1] - The company was registered on June 23, 2020, and issued 61,621,142 shares of ordinary stock to the public, which were listed on the Shanghai Stock Exchange on July 22, 2020 [1][3] - The registered capital of the company is RMB 616,785,793 [2] Business Objectives and Scope - The company's business objective is to focus on patients, quality, and innovation, aiming to become a leader in the antibody drug field in China [3] - The business scope includes medical research and development, technical services, drug production, import and export, and medical device operations [4][5] Shares - The company's shares are issued in the form of stocks, with each share having a par value of RMB 1 [6][7] - The total share capital of the company is RMB 616,785,793, with a total of 616,785,793 shares, all of which are ordinary shares [7][8] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, supervision of company operations, and access to company documents [12][13] - Shareholders must comply with laws and the company's articles of association, and they cannot withdraw their capital except as legally permitted [15] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with specific procedures for calling and conducting these meetings [21][22] - Shareholder meetings require a quorum and must follow legal and procedural requirements for decision-making [36][37] Financial Assistance and Guarantees - The company may provide financial assistance for acquiring its shares under certain conditions, but the total amount cannot exceed 10% of the issued share capital [8] - Any external guarantees provided by the company must be approved by the shareholders if they exceed specified thresholds [46][47]

董事、高级管理人员薪酬管理制度 第一章 总则 三生国健药业（上海）股份有限公司 董事、高级管理人员薪酬管理制度 三生国健药业（上海）股份有限公司 第一条 为进一步完善三生国健药业（上海）股份有限公司（以下简称"公司"） 董事、高级管理人员的薪酬、津贴管理，建立科学有效的激励与约束机制，有效 调动公司董事、高级管理人员的工作积极性，提高公司的经营管理效益，根据《中 华人民共和国公司法》《上市公司治理准则》《上海证券交易所科创板股票上市 规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等 有关法律法规、规范性文件和《三生国健药业（上海）股份有限公司章程》（以 下称"《公司章程》"）的相关规定，结合公司实际情况，制定本薪酬管理制度。 第二条 本制度适用于公司章程规定的董事、高级管理人员。 第三条 公司董事、高级管理人员的薪酬以公司经营与综合管理情况为基础， 根据经营计划完成情况、分管工作职责及工作目标完成情况、个人履职及发展情 况相结合进行综合考核确定。 第四条 公司董事、高级管理人员薪酬分配遵循以下原则： （一）公平原则，薪酬水平符合公司规模与业绩的原则，同时与市场薪酬水 平相符； （二） ...

General Principles - The management system for the shares held by the directors and senior management of the company is established to strengthen the management of shareholding and its changes, in accordance with relevant laws and regulations [1][2] - This system applies to the shares held by the company's directors and senior management, including shares registered in their names and those held through others' accounts [2] Prohibited Share Transfer Conditions - Directors and senior management are prohibited from transferring shares under certain conditions, such as within one year of the company's stock listing or within six months after leaving the company [2][3] - Additional prohibitions include situations involving investigations by regulatory authorities or administrative penalties related to securities violations [2] Trading Restrictions - Directors and senior management cannot trade company shares during specific periods, including 15 days before the announcement of annual or semi-annual reports and 5 days before quarterly reports [3] - They must also ensure that close relatives and controlled entities do not trade based on insider information [4] Reporting and Disclosure Requirements - Directors and senior management must report their shareholding changes within two trading days through the company to the Shanghai Stock Exchange, detailing the number of shares before and after the change, the date, price, and reason for the change [7][8] - A reduction plan must be reported 15 trading days in advance, including details such as the number of shares to be reduced and the reasons for the reduction [8] Compliance and Accountability - The company’s board secretary is responsible for managing the identity and shareholding data of directors and senior management, ensuring compliance with reporting requirements [9] - If the board fails to comply with regulations, shareholders have the right to demand action or take legal action [5][6]

华泰联合证券有限责任公司 关于三生国健药业（上海）股份有限公司 部分募投项目完成承诺募集资金投入并将节余募集资金 永久补充流动资金的专项核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为 三生国健药业（上海）股份有限公司（以下简称"三生国健"、"公司"或"发行人"） 首次公开发行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管 理办法》、《上市公司募集资金监管规则》、《上海证券交易所科创板股票上市规则 （2025 年 4 月修订）》及《上海证券交易所科创板上市公司自律监管指引第 1 号 ——规范运作（2025 年 5 月修订）》等法律法规的规定，对三生国健部分募投项 目完成承诺募集资金投入并将节余募集资金永久补充流动资金事项进行了审慎核 查，核查情况及核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2020 年 6 月 23 日出具的《关于同意三生国 健药业（上海）股份有限公司首次公开发行股票注册的批复》（证监许可 [2020]1217 号），公司获准向社会公开发行人民币普通股（A 股）61,621,142 股， 发行价为每股人民币 28.18 元， ...

三生国健药业（上海）股份有限公司 2025 年半年度报告 1 / 147 公司代码：688336 公司简称：三生国健 三生国健药业（上海）股份有限公司 2025 年半年度报告 三生国健药业（上海）股份有限公司 2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司核心竞争力风险、经营风险及行业风险等风险因素，敬请查 阅本报告第三节"管理层讨论与分析"之"风险因素",并提请投资者特别关注如下风险： 1、创新药研发面临不确定性以及较大市场竞争的风险 创新药研发具有研发周期长、投入大、风险高、成功率低的特点，从立项到新药获批上市要 经过临床前研究、临床试验、新药注册上市和售后监督等诸多复杂环节，每一环节都有可能面临 失败风险。另外，考虑到药物研发风险以及未来产品上市面临市场竞争的不确定性，若公司无法 有效利用自身的研发技术经验、规模化生产优势或终端销售覆盖能力，则可能导致在研产品无法 在同靶点产品中抢先获批上市，相关产品将面 ...

股东会议事规则 三生国健药业（上海）股份有限公司 （三）审议批准公司的利润分配方案和弥补亏损方案； （四）对公司增加或者减少注册资本作出决议； （五）对发行公司债券作出决议； （六）对公司合并、分立、解散、清算或者变更公司形式作出决议； 第一章 总则 第一条 为维护三生国健药业（上海）股份有限公司（以下简称"公司"） 股东合法权益，明确股东会的职责权限，保证股东会依法行使职权，根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股东会规则》《上海证券交易所科创 板上市公司自律监管指引第 1 号——规范运作》和《三生国健药业（上海）股份 有限公司章程》（以下简称"《公司章程》"）以及国家的相关法律、法规及规 范性文件的规定，制定本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、法规、《公司章程》及本规则的相关规定 召开股东会，保证股东能够依法行使权利。公司董事会应当切实履行职责，认真、 按时组织股东会。公司全体董事应当勤勉尽责，确保股东会正常召开和依法行使 职权。 第四条 股东会是公司的最高 ...

三生国健药业（上海）股份有限公司章程 （2025 年 8 月） 第一章 总则 第一条 为维护三生国健药业（上海）股份有限公司（以下简称"公司"或 "上市公司"）、股东、职工和债权人的合法权益，规范公司的组织和行为，根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司以发起方式设立，在上海市市场监督管理局注册登记，取得营业执照， 统一社会信用代码 91310000735408592G。 第三条 公司于 2020 年 6 月 23 日经中国证券监督管理委员会注册，首次向 社会公众发行人民币普通股 61,621,142 股，均为公司向境内投资人发行的人民币 认购的内资股，并于 2020 年 7 月 22 日在上海证券交易所科创板上市。 第四条 公司注册名称：三生国健药业（上海）股份有限公司 公司英文名称：SUNSHINE GUOJIAN PHARMACEUTICAL.（SHANGHAI） Co., Ltd. 第五条 公司住所：中国（上海）自由贸易试验区李冰路 3 ...